Dermatomyositis and systemic lupus erythematosus are autoimmune disorders of uncertain cause and without specific medical therapy, generally treated with non-specific immunosuppressive medications that have significant complications. We have studied muscle and blood samples from patients with dermatomyositis and other inflammatory myopathies, and believe that overproduction of interferon alpha and beta (IFN-a/b) by plasmacytoid dendritic cells is responsible for tissue injury in dermatomyositis specifically. ? ? Other investigators studying systemic lupus erythematosus (SLE) have also hypothesized that such overproduction of IFN-a/b is in part responsible for the manifestations of that disease. We propose to use high-throughput drug discovery methods to identify compounds of predicted efficacy for DM and SLE. Development of such compounds into safe and effective drugs for the treatment of DM and SLE is the long-term objective of this work. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AR056626-01A2
Application #
7467797
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Mancini, Marie
Project Start
2008-09-30
Project End
2010-05-31
Budget Start
2008-09-30
Budget End
2009-05-31
Support Year
1
Fiscal Year
2008
Total Cost
$192,500
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Liao, Anne P; Salajegheh, Mohammad; Morehouse, Chris et al. (2010) Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin Immunol 136:130-8